Targeted Therapeutic Strategies for Recurrent Glioblastoma

Recurrent glioblastoma presents a formidable clinical challenge due to its intrinsic heterogeneity, aggressive nature and resistance to conventional treatments. Targeted therapeutic strategies aim to exploit vulnerabilities in tumour biology by directing agents against specific molecular drivers, cell populations or microenvironmental factors. Key approaches include inhibition of dysregulated receptor tyrosine kinases, modulation of aberrant signalling cascades, targeting of cancer stem cells that repopulate the tumour mass, and disruption of tumour vasculature through anti-angiogenic agents. Precision medicine efforts increasingly integrate genomic, epigenomic and proteomic profiling to match patients with agents that are most likely to achieve durable responses. Combination regimens that marry small-molecule inhibitors with immunomodulatory techniques, such as CAR T cell therapy or oncolytic virotherapy, show promise in preclinical models. Biomarker-driven patient selection has begun to refine clinical trial design, focusing on patients whose tumours harbour alterations in pathways such as EGFR, PI3K/AKT/mTOR or PDGFR. Despite advances in understanding, obstacles remain, including the blood–brain barrier, adaptive resistance mechanisms and intratumoral variability. The global significance of this work lies in its potential to extend survival, preserve neurological function and usher in truly personalised care for patients confronting this refractory disease.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Targeted Therapeutic Strategies for Recurrent Glioblastoma publication trend

The graph below shows the total number of articles in targeted therapeutic strategies for recurrent glioblastoma across all publications each year (not limited to Nature Index journals).

Technical terms

Receptor tyrosine kinase: A class of cell-surface enzymes that transduce extracellular signals into intracellular pathways driving growth and survival.

Cancer stem cell: A subpopulation of tumour cells with self-renewal capacity, often resistant to standard therapies and implicated in recurrence.

CAR T cell therapy: A form of adoptive cell therapy in which patient T cells are engineered to express chimeric antigen receptors targeting tumour antigens.

Anti-angiogenic therapy: Treatment aimed at inhibiting the formation of new blood vessels within the tumour microenvironment to starve cancer cells of nutrients.

Biomarker: A measurable molecular indicator used to predict therapeutic response or disease progression.

References

1. From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress. Signal Transduction and Targeted Therapy (2023).
2. Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial. Cell Reports Medicine (2023).
3. Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma. Journal of Translational Medicine (2023).